Datwyler, LTS Device Technologies, and Stevanato Group have launched a collaboration to broaden self-administration options for large-volume therapies, including biologics and oncology treatments. The partnership aims to enable on-body delivery of higher-dose therapies while maintaining safety, patient comfort, and therapeutic efficacy.

The companies will demonstrate their integrated platform at Pharmapack Europe 2026 in Paris, with a Learning Lab presentation titled: When Size Matters: The Evolution of Self-Delivery Solutions for Subcutaneous Administration.

Subcutaneous drug delivery is increasingly shifting from hospital settings to home-based care, driven by patient preferences and the growing use of biologics. A Mayo Clinic study found that 73% of participants preferred self-administration at home after 24 weeks of therapy. Higher-volume therapies, such as monoclonal antibodies and oncology treatments, have traditionally been limited to 2mL injections due to tissue tolerability and absorption kinetics.

Paolo Ferrigno, product manager for PFS & Cartridges at Datwyler, said: “By enabling patients to self-administer therapies at home, subcutaneous drug administration facilitates a growing shift towards more accessible personalized healthcare. Datwyler’s spray coated NeoFlex plungers increase the functional reliability of large volume injection systems and promote greater comfort and safety for the patients.”

The collaboration combines Datwyler’s NeoFlex plungers with Stevanato Group’s ready-to-use large-volume EZ-fill cartridges and LTS Device Technologies’ Sorrel Platform. This pre-verified ecosystem allows pharmaceutical manufacturers to accelerate time to market while addressing the operational challenges of high-volume, sensitive therapies.

Riccardo Marcon, senior vice president of sales & marketing, Drug Containment Solutions, Stevanato Group, said: “There is a pressing market need for innovative solutions to support larger volumes of up to 20mL in a self-administered setting while strictly maintaining safety, therapeutic efficacy, and patient compliance. For pharma companies, EZ-fill large-volume cartridges have been the ideal solution to reduce their complex operations for more than a decade.”

The integrated platform is designed to support slower, controlled delivery of larger doses, facilitating patient-centric healthcare and expanding options for therapies traditionally confined to hospital administration.